| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
The primary target of Buformin hydrochloride is glucose metabolism. It acts as a biguanide antihyperglycemic agent, delaying glucose absorption from the gastrointestinal tract, increasing insulin sensitivity and glucose uptake into cells, and inhibiting hepatic gluconeogenesis. The compound's mechanism of action is similar to that of metformin.
|
|---|---|
| ln Vitro |
The concentration-dependent inhibition of SKBR3 and BT474 cell growth is observed with buformin hydrochloride (0-10 mM; 5 days); IC50s for erbB-2-overexpressing SKBR3 and BT474 cells are 246.7 μM and 98.6 μM, respectively [1]. Buformin hydrochloride (0–3 mM; 48 hours) reduces the percentage of cells in the S phase and raises the proportion of cells in the G0/G1 phase, particularly in SKBR3 cells [1]. As well as inhibiting Akt activation/phosphorylation in SKBR3 and BT474 cells, buformin hydrochloride (0-3 mM; 24 hours) inhibits RTK activation, including downstream erbB-2 and IGF1R signaling [1].
In vitro, Buformin hydrochloride has been shown to have antihyperglycemic activity. It delays absorption of glucose and increases insulin sensitivity in peripheral cells. The compound's effects on glucose metabolism have been confirmed in various in vitro models. |
| ln Vivo |
In MMTV-erbB-2 transgenic mice, buformin hydrochloride (oral; 7.6 mmol/kg, mixed in diet; 7 days) dramatically lowers tumor volume and weight and inhibits the growth and morphogenesis of the mammary glands [1].
In vivo, Buformin hydrochloride is used as an oral hypoglycemic agent for the treatment of type 2 diabetes mellitus. It delays absorption of glucose from the gastrointestinal tract, increases insulin sensitivity and glucose utilization in peripheral cells, and inhibits hepatic gluconeogenesis. The compound has potential therapeutic effects in various diseases, including diabetes and cancer. |
| Enzyme Assay |
In vitro enzyme or receptor binding assays for Buformin hydrochloride are not commonly performed, as it is not a direct enzyme inhibitor or receptor ligand. Its effects on glucose metabolism are assessed in cell-based assays. The compound's ability to increase glucose uptake and inhibit gluconeogenesis is measured in cultured cells.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: ErbB-2-overexpressing SKBR3 and BT474 cells Tested Concentrations: 0 μM, 1 μM, 3 μM, 10 μM, 30 μM, 100 μM, 300 μM, 1, 3, or 10 mM Incubation Duration: 5 days Experimental Results: decreased cell viability in erbB-2-overexpressing breast cells. Cell Cycle Analysis[1] Cell Types: ErbB-2-overexpressing SKBR3 and BT474 cells Tested Concentrations: 0.5 mM; 1 mM; 3 mM Incubation Duration: 48 hrs (hours) Experimental Results: Increased cells arresting in G0/G1 phase. Western Blot Analysis[1] Cell Types: ErbB-2-overexpressing SKBR3 and BT474 cells Tested Concentrations: 0mM, 0.1mM, 0.3mM, 1mM, or 3mM Incubation Duration: 24 hrs (hours) Experimental Results: diminished p-AMPK, p-p706S, p-ERK1/2 expression in a concentration-dependent manner. In vitro cell-based assays for Buformin hydrochloride are performed using hepatocytes and other cell types. Cells are treated with the compound, and glucose uptake, gluconeogenesis, and insulin sensitivity are measured. The compound's effects on AMPK activation and other signaling pathways are assessed. |
| Animal Protocol |
Animal/Disease Models: Female MMTV-erbB-2 transgenic mice[1]
Doses: 7.6 mmol/kg Route of Administration: Oral administration; 7 days Experimental Results: Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice. In vivo animal experiments for Buformin hydrochloride are conducted using rodent models of type 2 diabetes. The compound is administered orally, and blood glucose levels, insulin sensitivity, and glucose tolerance are assessed. These studies confirm the compound's efficacy as an antihyperglycemic agent. |
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Buformin hydrochloride indicate that it has a molecular weight of 193.68 and a molecular formula of C6H16ClN5. The CAS number is 1190-53-0. The IUPAC name is 1-Butylbiguanide monohydrochloride. It is a solid at room temperature. Storage at room temperature is recommended.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for Buformin hydrochloride indicate that it is generally well-tolerated. Common side effects may include gastrointestinal disturbances, such as nausea and diarrhea. The compound may also cause lactic acidosis, a rare but serious side effect. It should be used with caution in patients with renal impairment.
|
| References |
|
| Additional Infomation |
Butylmethoxazole hydrochloride is the hydrochloride salt form of Butylmethoxazole, a biguanide hypoglycemic drug. Butylmethoxazole is not metabolized and is primarily excreted in the urine. This drug carries a high risk of lactic acidosis and has been withdrawn from the market. It is an oral hypoglycemic agent that inhibits gluconeogenesis, promotes glycolysis, and reduces glucose oxidation.
Other information: Buformin hydrochloride is a biguanide antidiabetic agent. It is also known as N-butyl Biguanide. The compound is similar to metformin and phenformin. Its UNII is D947SXO87P. Its CAS number is 1190-53-0. |
| Molecular Formula |
C6H16CLN5
|
|---|---|
| Molecular Weight |
193.68
|
| Exact Mass |
193.109
|
| CAS # |
1190-53-0
|
| Related CAS # |
Buformin;692-13-7
|
| PubChem CID |
84976
|
| Appearance |
Light yellow to green yellow solid powder
|
| Boiling Point |
322.7ºC at 760 mmHg
|
| Melting Point |
174-177ºC
|
| Flash Point |
148.9ºC
|
| Vapour Pressure |
0.000275mmHg at 25°C
|
| LogP |
2.277
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
12
|
| Complexity |
156
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KKLWSPPIRBIEOV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H15N5.ClH/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11)1H
|
| Chemical Name |
1-Butylbiguanide monohydrochloride
|
| Synonyms |
NSC 528218 Silubin NSC-528218Buformin hydrochloride NSC528218
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~645.39 mM)
H2O : ~100 mg/mL (~516.32 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (516.32 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1632 mL | 25.8158 mL | 51.6316 mL | |
| 5 mM | 1.0326 mL | 5.1632 mL | 10.3263 mL | |
| 10 mM | 0.5163 mL | 2.5816 mL | 5.1632 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
